Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice.

doi:10.1016/j.bbrc.2021.04.062

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice.

Biochemical and biophysical research communications - 25 Jun 2021

Ohya Kazuki, Imamura Michio, Teraoka Yuji, Uchida Takuro, Fujino Hatsue, Nakahara Takashi, Ono Atsushi, Murakami Eisuke, Yamauchi Masami, Kawaoka Tomokazu, Miki Daiki, Tsuge Masataka, Abe-Chayama Hiromi, Hayes C Nelson, Aikata Hiroshi, Ishida Yuji, Tateno Chise, Song HoJoong, Miyayama Yohei, Hijikata Makoto, Chayama Kazuaki

Abstract excerpt

Combination therapy with glecaprevir and pibrentasvir (PIB) has high efficacy for patients with hepatitis C virus (HCV) infection except among those who experienced NS5A-P32 deletion (del) mutation during prior DAA treatment failure. However, some patients fail to achieve SVR through combination treatment even in the absence of NS5A-P32del. We analyzed emergence of NS5A resistance-associated substitutions (RASs)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzimidazoles

Share to Drug Resistance, Viral

Share to Pyrrolidines

Source

Open in PubMed

Identifiers

PMID: 33932902
DOI: 10.1016/j.bbrc.2021.04.062

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice.PMID 33932902Read ↗

NS5A-P32 Deletion in Hepatitis C Genotype 1b Infection is the Most Refractory Treatment-Mediated Amino Acid Change Exhibiting Resistance to all NS5A Inhibitors.Semantic proximity Read ↗

Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.Semantic proximity Read ↗

Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.Semantic proximity Read ↗

Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.Semantic proximity Read ↗

Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.Semantic proximity Read ↗

Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment.Semantic proximity Read ↗

Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures.Semantic proximity Read ↗

Antiviral Treatment Failures After Transplantation of Organs From Donors With Hepatitis C Infection: A Report of 4 Cases.Semantic proximity Read ↗

Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice.Semantic proximity Read ↗

Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA.Semantic proximity Read ↗

<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor PibrentasvirSemantic proximity Read ↗

Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.